Prosecution Insights
Last updated: November 20, 2026
Application No. 17/622,121

COMPOUNDS HAVING ANTIMALARIAL ACTIVITY

Non-Final OA §112
Filed
Dec 22, 2021
Priority
Jun 27, 2019 — SG 10201905970U +1 more
Examiner
DAHLIN, HEATHER RAQUEL
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nanyang Technological University
OA Round
4 (Non-Final)
42%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
71 granted / 168 resolved
-17.7% vs TC avg
Strong +47% interview lift
Without
With
+46.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
49 currently pending
Career history
231
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
35.0%
-5.0% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 168 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Foreign Priority This Application is a 371 of PCT/SG2020/050368, filed 06/25/2020 and claims foreign priority to SG10201905970U, filed 06/27/2019 in the Republic of Singapore. Claim Status Claims 1, 3-4, 6-9, 11, 13 and 15-18 are currently pending and subject to examination. Claim Rejections – Withdrawn – Overcome by Amendment The rejection of claim 9 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends is withdrawn. The rejection of claim(s) 1, 3, 4, 7, 8 and 16 under 35 U.S.C. 102(a)(1) as being anticipated by Grassi et al. (ChemEurJ, Vol. 19, Issue 4, January 21, 2013, pp. 1466-75) is withdrawn. The rejection of claim(s) 9 under 35 U.S.C. 102(a)(1) as being anticipated by He et al. (Organic Letters, Vol. 16, Issue 12, June 6, 2014, Supporting Information) is withdrawn. Withdrawn Indication of Allowable Subject Matter The indication in the Office Action mailed June 1, 2026 that claims 5, 6, 11, 13, 15, and 17-18 would be allowable if rewritten in independent form is withdrawn in view of the new grounds of rejection set forth below. Claim Rejections – 35 USC § 112(b) – New Grounds of Rejection The following is a quotation of 35 U.S.C. 112(b): “(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.” The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: “The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” Claims 1, 3, 4, 6-8, 11, 13, 15, 16, 17 and 18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 11 each recite that Y is independently selected from C-Rb, C-(Rb)2, N-Rb, and N and that “---” indicates a single or double bond. The claims do not link the selection of Y to the bond represented by “---“. As written, the claims therefore encompass combinations that do not describes any compound, including: Y as C(Rb)2 with “---” a double bond, which gives a pentavalent carbon, Y as N-Rb with “---” a double bond, which gives a nitrogen with four bonds, and Y as N with “---” a single bond, which gives a nitrogen with two bonds. A claim, although clear on its face, may be indefinite when a conflict or inconsistency between the claimed subject matter and the specification disclosure renders the scope of the claim uncertain. See MPEP § 2173.03. The specification confirms that the Applicant does not regard these combinations as part of the invention. The specification states that the selection of Y “is furthermore influences by n and whether ‘---’ is a single or double bond” and that when n is 1 and “---” is a double bond, Y is selected from C-Rb and N, and when n is 1 and “---” is a single bond, Y is selected from C(Rb)2 and N-Rb. (Published Specification, paragraph [0101]). The claims omit this limitation. Under the broadest reasonable interpretation, claims 1 and 11 encompass Y/ bond combinations that the specification excludes and that are chemically impossible. One of ordinary skill in the art therefore cannot determine whether the claims are limited to the combinations set for in paragraph [0101] or extend to all combinations literally recited. Therefore, the metes and bounds of the claims cannot be determined. Claims 3, 6-8, 13, 15, 16 and 18 depend from claim 1 or claim 11 and do not further limit Y or “---” and are therefore rejected for the same reasons. Claims 4 and 17 are further rejected as indefinite because claim 4, alternative (2), recites that Y is CRb and “---” is a single bond. The specification states that when “---” is a single bond, Y is selected from C(Rb)2 and N-Rb (Published Spec., para. [0101]). CRb and Ch are not among these. The specification also states that when the double bond is not present “the carbon atom carrying the Ra substituent additionally is bound to a hydrogen.” (Published Spec., para. [0104]). Ra, however, is a substituent of X, not Y. One of ordinary skill in the art cannot determine with reasonable certainty the structure of the compounds of claims 4 and 17 because the specification is internally inconsistent as to whether, and how, Y may be CRb or CH when “---” is a single bond. See MPEP § 2173.03. Claim Rejections – 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): “(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.” The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.” Claims 1, 3, 4, 6-8, 11, 13, and 15-18 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for compounds of formula (I) wherein n is 1, Y is N and “---” is a double bond (i.e. wherein each heteroalicyclic ring is 2-imidazoline), does not reasonably provide enablement for compounds wherein Y is C-Rb, C-(CRb)2 or N-Rb. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The sole utility asserted for the claimed compounds is in the treatment or prevention of malaria. (Published Spec., paras. [0002], [0123]-[0125]). A claimed compound must be enabled for its asserted use. MPEP § 2164.01(c). The specification must enable the full scope of the asserted claims without undue experimentation. Amgen Inc. v. Sanofi, 598 U.S. 594, 610-612 (2023). Whether experimentation is undue is determined by the factor set forth in In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988). Those factors are considered below. (1) Breadth of the claims; (2) nature of the invention. The claims encompass compounds wherein each of the five-membered rings is an imidazoline (Y is N), an N-substituted imidazoline or dihydroimidazole (Y is N-Rb), a pyrrolidine (Y is C-(Rb)2) or a dihydropyrrole (Y is C-Rb). Rb is selected from more than twenty substituent classes. Each ring is selected independently, and R2, R3, R4, R8, R9 and R10 are broadly defined. The claims thus encompass a very large number of structurally diverse compounds. (3) State of the prior art; (4) level of predictability. The art of predicting antiparasitic activity from chemical structure is unpredictable. See In re Fisher, 427 F.2d 833, 839 (CCPA 1970). Applicant’s own data confirm this unpredictability, showing that minor structural changes to the heterocyclic ring abolish or drastically reduce activity: Replacing the 4,5-diphenyl-2-imidazoline rings of the lead compound with aromatic 4,5-disphenylimidazole rings reduced activity from about 120 nM to about 4,690 nM. (Published Spec, para. [0170]; Fig. 7). An analog bearing unsubstituted imidazole rings showed no growth inhibition (Fig. 7B). Bis-oxazoline analogs, in which an oxygen atom occupies a ring position, showed no or only weak inhibition (<40% inhibition). (Fig. 7A). Replacing the methylene linker with a carbonyl reduced activity to 5,042 nM. (Published Spec., para. [0170]; Fig. 7B). Compounds wherein Y is carbon or N-Rb lack the cyclic amidine (N-C=N) common to every active compound disclosed. Replacing the amidine with a cyclic tertiary amine (Y= C-(Rb)2) eliminates the delocalized amidinium cation and the sp2 hydrogen bond acceptor and changes ring geometry while replacement with an enamine (Y= C-Rb) also substantially reduces basicity. Applicant’s demonstration that even oxidation of the imidazoline to an imidazole reduces activity roughly forty-fold, one of ordinary skill in the art could not predict that compounds wherein Y is C-Rb, C-(Rb)2 or N-Rb would possess antimalarial activity. (5) Amount of direction provided; (6) presence of working examples. Every compound tested that falls within formula (I) has Y as N and “---” as a double bond. (Published Spec., paras. [0142], [0170]-[0172]; Figs. 1-8. The specification provides no working example, biological data, or structure-activity guidance for any compound wherein Y is C-Rb, C-(Rb)2 or N-Rb. As to making the compounds, the specification only states that the compounds of formula (I) can be prepared as generally reported in He et al. (Org. Lett. 2014, 16, 3244-3247 (of record)). (Published Spec., para. [0139]). That method uses the imidazoline ring and does not prepare rings in which Y is carbon or N-Rb (see supporting information, scheme 1). (7) Level of skill in the art. The level of skill in the art is high, PhD level medicinal chemists, who would have experience in organic synthesis and structure-activity studies. The high level of skill does not overcome the unpredictability demonstrated by Applicant’s own data. (8) Quantity of experimentation. To practice the full scope of the claims, one of ordinary skill in the art would have to design synthetic routes to each class of ring for which no route is disclosed, prepare compounds bearing the many permitted substituents, and screen each for antimalarial activity. Based on Applicant’s own results, there is no reasonable expectation that the compounds would be active. Such a research program constitutes undue experimentation. Weighing all the Wands factors, the specification does not enable the full scope of claims 1, 3, 4, 6-8, 11, 13 and 15-18. Allowable Subject Matter Claims 9 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 1, 3, 4, 6-8, 11, 13, and 15-18 are rejected. Claim 9 is objected to as being dependent on a rejected base claim. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HEATHER DAHLIN whose telephone number is (571)270-0436. The examiner can normally be reached 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached on (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 86-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HEATHER DAHLIN/Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Show 2 earlier events
Nov 26, 2025
Response Filed
Jan 09, 2026
Final Rejection mailed — §112
Apr 09, 2026
Request for Continued Examination
Apr 13, 2026
Response after Non-Final Action
Jun 01, 2026
Non-Final Rejection mailed — §112
Sep 01, 2026
Response Filed
Oct 14, 2026
Examiner Interview (Telephonic)
Nov 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773407
Methods of Managing Cocaine or Other Drug Addictions
3y 8m to grant Granted Oct 27, 2026
Patent 12760023
CYCLIN-DEPENDENT KINASE INHIBITORS
5y 3m to grant Granted Oct 13, 2026
Patent 12753174
CRYSTALLINE FORM OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR
3y 0m to grant Granted Oct 06, 2026
Patent 12729193
TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4
3y 4m to grant Granted Sep 08, 2026
Patent 12703686
4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME
3y 4m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
42%
Grant Probability
89%
With Interview (+46.6%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 168 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month